Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders

被引:12
作者
Larner, AJ [1 ]
机构
[1] Charing Cross Hosp, Dept Clin Neurosci, London W6 8RF, England
关键词
aggregation; Alzheimer's disease; amyloidosis; conformational change; paired helical filaments; protein kinase inhibitors; tauopathy; tau protein;
D O I
10.1517/13543776.9.10.1359
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The microtubule associated protein tau is the key component of the neurofibrillary pathology seen in Alzheimer's disease (AD) and other rare causes of dementia. Increased understanding of the physiology and pathophysiology of tau has opened up the possibility of targeting this molecule for therapeutic purposes in AD and related disorders. Two principal lines of investigation have been pursued: preventing the hyperphosphorylation of tau molecules, which is observed in tau extracted From AD brain; and preventing the aggregation of tau molecules into the paired helical filaments (PHFs), which constitute neurofibrillary change. The discovery of tate gene mutations as a rare cause of neurodegenerative disease has added impetus to research in this area.
引用
收藏
页码:1359 / 1370
页数:12
相关论文
共 105 条
[91]  
1996, Patent No. 9616052
[92]  
1998, Patent No. 9825640
[93]  
1996, Patent No. 9604915
[94]  
1997, Patent No. 8958909
[95]  
1996, Patent No. 9615791
[96]  
1998, EXP OPIN THER PATENT, V8, P729
[97]  
1995, Patent No. 9535366
[98]  
1997, Patent No. 9712992
[99]  
1997, Patent No. 9741854
[100]  
1996, Patent No. 9601114